Literature DB >> 20395862

Cohort study of the survival benefit of resection for recurrent hepatic and/or pulmonary metastases after primary hepatectomy for colorectal metastases.

Yoshihiro Mise1, Hiroshi Imamura, Takuya Hashimoto, Yasuji Seyama, Taku Aoki, Kiyoshi Hasegawa, Yoshihumi Beck, Yasuhiko Sugawara, Masatoshi Makuuchi, Jun Nakajima, Norihiro Kokudo.   

Abstract

OBJECTIVE: To evaluate resection for hepatic and/or pulmonary recurrences in a cohort that underwent initial hepatectomy for colorectal liver metastases. SUMMARY BACKGROUND DATA: The survival benefit of repeated resections for hepatic and/or pulmonary recurrences after initial hepatectomy for colorectal liver metastases has remained unclear.
METHODS: Recurrence occurred in 166 of the 216 patients after the first hepatectomy. Repeated resections were performed in 98 patients. We investigated the pattern of recurrence, the proportion of patients who underwent repeated resection, and the surgical outcome.
RESULTS: Of the 166 patients with recurrence, 71 had isolated hepatic recurrence, 25 had isolated pulmonary recurrence, 13 had hepatic plus pulmonary recurrence, and 57 had recurrence in other organs. Repeated resections were conducted in 60 (85%) patients with isolated hepatic recurrence, 21 (84%) with isolated pulmonary recurrence, and 9 (69%) with both hepatic and pulmonary recurrence. The 5-year survival rates after repeated resection were 39%, 37%, and 20% for isolated hepatic recurrence, isolated pulmonary recurrence, and hepatic plus pulmonary recurrence, respectively. Multivariate analysis revealed that the following variables contributed to poor prognosis (hazard ratio [95% confidence interval]): number of recurrent tumors (1.20 [1.11-1.29]), maximum size of recurrent tumors (1.26 [1.02-1.48]), pulmonary recurrence (2.36 [1.41-3.20]), and hepatic plus pulmonary recurrence (4.01 [2.86-.17]).
CONCLUSIONS: Patients with pulmonary or hepatic plus pulmonary recurrence had poorer prognoses than those with isolated hepatic recurrence. Reresection is the only potentially curative treatment. Stricter indication criteria, especially regarding the number of tumor nodules, can lead to comparable long-term outcomes.

Entities:  

Mesh:

Year:  2010        PMID: 20395862     DOI: 10.1097/SLA.0b013e3181c9868a

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  21 in total

1.  Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis.

Authors:  Chien-Hsin Chen; Mao-Chih Hsieh; Wilson T Lao; En-Kwang Lin; Yen-Jung Lu; Szu-Yuan Wu
Journal:  Am J Cancer Res       Date:  2018-09-01       Impact factor: 6.166

Review 2.  Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone?

Authors:  Khurum Khan; Anita Wale; Gina Brown; Ian Chau
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

3.  Hobson's choice two-stage hepatectomy for multiple and bilobar colorectal liver metastases with portal vein embolization: report of two cases.

Authors:  Suguru Yamashita; Kiyoshi Hasegawa; Michiro Takahashi; Junichi Arita; Yoshihiro Sakamoto; Taku Aoki; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Surg Today       Date:  2014-06-19       Impact factor: 2.549

4.  Determinants of repeat curative intent surgery in colorectal liver metastasis.

Authors:  Afif N Kulaylat; Neil H Bhayani; Audrey L Stokes; Jane R Schubart; Joyce Wong; Eric T Kimchi; Kevin F Staveley-O'Carroll; Jussuf T Kaifi; Niraj J Gusani
Journal:  J Gastrointest Surg       Date:  2014-06-21       Impact factor: 3.452

5.  Surgical salvage of recurrence after resection of colorectal liver metastases: incidence and outcomes.

Authors:  Nuh N Rahbari; Michael I D'Angelica
Journal:  Hepat Oncol       Date:  2017-08-03

6.  Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma.

Authors:  Hirofumi Ichida; Hiroshi Imamura; Jiro Yoshimoto; Hiroyuki Sugo; Yoshiaki Kajiyama; Masahiko Tsurumaru; Kenji Suzuki; Yoichi Ishizaki; Seiji Kawasaki
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

7.  Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model.

Authors:  Uwe Pohlen; Heinz J Buhr; Gerd Berger; Jörg-Peter Ritz; Christoph Holmer
Journal:  Invest New Drugs       Date:  2011-03-01       Impact factor: 3.850

8.  Repeat liver resection for recurrent colorectal metastases: a single-centre, 13-year experience.

Authors:  Narendra Battula; Dimitrios Tsapralis; David Mayer; John Isaac; Paolo Muiesan; Robert P Sutcliffe; Simon Bramhall; Darius Mirza; Ravi Marudanayagam
Journal:  HPB (Oxford)       Date:  2013-03-27       Impact factor: 3.647

9.  One-stage hepatectomy following portal vein embolization for colorectal liver metastasis.

Authors:  Suguru Yamashita; Kiyoshi Hasegawa; Michiro Takahashi; Yosuke Inoue; Yoshihiro Sakamoto; Taku Aoki; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

10.  Repeat liver resection after a hepatic or extended hepatic trisectionectomy for colorectal liver metastasis.

Authors:  Oliver Ziff; Ibrahim Rajput; Robert Adair; Giles J Toogood; K Rajendra Prasad; J Peter A Lodge
Journal:  HPB (Oxford)       Date:  2013-07-22       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.